Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 29, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 810,000 ordinary shares of 25 pence each.
- Purchase Price: 1,161.37 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,216,447,108 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 810,000 shares purchased on October 29, 2008. This action was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008. Consequently, the number of shares in issue was updated to 5,216,447,108.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 810,000 share repurchase based on the disclosed price of 1,161.37 pence per share.
- Confirm the updated total voting rights denominator (5,216,447,108 shares) for disclosure threshold calculations.
- Note that Treasury shares now represent 9.09% of total voting rights.
- Recognize that this filing does not contain operational or financial performance data for the period.